failed_experiment.db
← Back to browse

Medicine› Infectious Diseases› COVID-19 Clinical Research Studies

COVID-19 — Azithromycin (immunomodulatory use)

Submitted 2026-10-22

Field: Medicine › Infectious DiseasesType: No effect foundArea: covid-19Target: Azithromycin (immunomodulatory use)Stage: randomized trial

Hypothesis

Because of its immunomodulatory effects, azithromycin 500 mg daily for up to 10 days would lower 28-day mortality in patients hospitalised with COVID-19.

What failed

In the RECOVERY platform trial, 7763 patients were randomised (2582 azithromycin, 5181 usual care); 22% died within 28 days in each arm (rate ratio 0.97, 95% CI 0.87-1.07, p = 0.50). Length of stay and the proportion discharged alive within 28 days also did not differ.

Broken assumption

Azithromycin's anti-inflammatory activity is strong enough to change survival in hospitalised COVID-19.

Why

The abstract reports no benefit and does not offer a mechanistic explanation.

From the published paper: Abaleke et al. The Lancet, 2021. ↗CC BY

Research ideas from this failure

Unvetted lead — read the papers

New hypotheses this failure suggests, each with a crucial experiment, a rival explanation of the original result, and the papers it rests on. Written by AI from paper titles and abstracts found on OpenAlex (and Europe PMC, for life and health sciences).

Related failures (3)

Matched on shared genes, mechanisms and ways of failing as well as wording. Each shows why it matched — treat these as leads rather than verdicts.

Links in published research

Where this experiment's genes are known to matter outside its own research area, and the papers behind those links. Sources: Open Targets Platform and Europe PMC.